

FOR IMMEDIATE RELEASE



October 16, 2013

AnGes MG, Inc.

Pre-clinical Study Results of Collatogene[®] (HGF Gene Drug Treatment) for Lymphedema Published in a Medical Journal

AnGes MG, Inc. ("AnGes") is pleased to announce that pre-clinical study results of the pharmacological function of the hepatocyte growth factor (HGF) plasmid, Collatogene[®], as a treatment for lymphedema has been published in *BioMed Research International* (Volume 2013, Article ID 804675), a biomedical journal.

The first author of the paper is Dr. Yukihiro Saito, a lecturer at the Department of Surgery, Asahikawa Medical University, and the inventor of the HGF plasmid's lymphangiogenesis function. This review paper highlights the pathophysiology of lymphedema, and discusses that "therapeutic lymphangiogenesis," a method using cytokines promoting lymphatic vessel regeneration, should be an effective approach as a therapy against this intractable disease. The review introduces the results of the pharmacological function of Collatogene[®] using an animal model of lymphedema, and suggests that HGF gene therapy may be a promising treatment for lymphedema.

To review the article:

<http://www.hindawi.com/journals/bmri/2013/804675/ref/>

AnGes is currently undertaking a Phase I/II study of Collatogene[®] in Japan for "primary lymphedema," as the world's first gene therapy for this intractable disease in which there is no effective treatment currently available for patients.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 http://www.anges-mg.com Email: info@anges-mg.com</p>
